Introduction: Patients with mixed dyslipidemia are presented with high levels of low-density lipid cholesterol (LDL-C), triglycerides (TG), and reduced high-density lipid cholesterol (HDL-C). Though useful in lowering LDL-C, therapy with rosuvastatin is insufficient in optimizing the overall lipid profile, thus putting the patient at risk of residual cardiovascular risk. A combination of statin with other lipid-modifying agents has been used with more efficient lipid control and cardiovascular risk prevention. Of these, fenofibric acid is the most frequently used, along with rosuvastatin.
Methods: Authors conducted a literature search of published literature to assess the use of rosuvastatin and fenofibrate combination in the management of mixed hyperlipidaemia.
Results and discussion: The authors selected a total of 46 articles to be included in the review. Due to the small number of articles and heterogeneity on the combination of rosuvastatin and fenofibrate combination in mixed hyperlipidemia, the findings herein are presented using narrative summaries. Based on the thorough assessment of the selected literature, the essential themes that emerged from the review include safety and efficacy of rosuvastatin and fenofibrate combination, place of therapy of rosuvastatin, and fenofibrate combination, and potential cardiovascular risk reduction with rosuvastatin and fenofibrate combination.
Conclusion: Based on the review, the authors suggested that the combination therapy with fenofibric acid was beneficial, well-tolerated with a similar safety profile compared with statin monotherapy. The combination therapy of moderate dose rosuvastatin and fenofibric acid led to a reduction of cardiovascular risk factors via several pathways.
A number of studies have reported that exact aetiology of non alcoholic fatty liver disease NAFLD is unknown. Serum uric acid is often incriminated as the etiological agent. Hence this study was taken up explore the role of BMI and serum uric acid in occurrence of NAFLD. A case control study was undertaken to compare the role of serum acid in occurrence of 100 NAFLD cases with 100 healthy volunteers. All the cases and controls were subjected for ultrasound examination and serum uric acid estimation with height and weight. Most of study subjects belonged to 21 – 40 years of age group and females outnumbered males. The Mean BMI among the cases was 25.34 (± 4.44) and controls was 25.12 (± 4.08). Mean serum uric acid level among the cases was 5.68 mg/dl and 4.14 mg/dl among the controls. BMI was more than 25 in 51% of the cases and 54% of the controls. Hyperurecemia was present in 37% of the NAFLD cases and 16% of the healthy volunteers. The author concludes that, the increased serum uric acid was demonstrated as risk factor for non alcoholic fatty liver disease.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.